Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

PharmaNutra S.p.A.: A Targeted Nutritional Supplement Proves To Aid Persistent Fatigue In Post-Covid Patients

April 12, 2021 GMT
1 of 2
ApportAL® (PRNewsfoto/PharmaNutra S.p.A.)
1 of 2
ApportAL® (PRNewsfoto/PharmaNutra S.p.A.)

PISA, Italy, April 12, 2021 /PRNewswire/ -- Fatigue is one of the most common symptoms lasting for months after the infection. This condition is independent of the age of the subject and severity of infection.

A recent study involving 200 patients in Italy suffering from post-Covid fatigue had the patients take nutritional supplement Apportal® (PharmaNutra SpA, Italy),which includes phytoextracts, amino acids, minerals and vitamins, for 28 consecutive days.

Quality of life and degree of fatigue were measured for each patient at 0, 14 and 28 days, while taking the supplement.


The FACIT-Fatigue questionnaire was used to assign an objective fatigue value to the long-COVID patients. It is made up of 13 statements relating to ability to perform everyday tasks, sleep needs during the day, energy and tiredness.

A second questionnaire created by re-adapting the Chalder Fatigue Scale was used to assess mental fatigue. These questions asked about memory, ability to concentrate and interest in activities performed before the infection.

The study was done with the assistance of general practitioners across Italy and included a wide age range of patients. Patients were also included no matter the severity of their previous infection or which variant of the virus they had had.

The study is currently in its final phase and analysis of the preliminary results are showing that taking Apportal® improved patients’ quality of life and reduced fatigue.

The data obtained through the use of the FACIT-Fatigue Test for the first 100 patients showed that 95% of patients measured a significant benefit. The score indicating their fatigue improved by 64%. Any differences among sexes was investigated and women suffered ‘more severe’ initial fatigue while showing a greater improvement in terms of mental fatigue. This is congruent with current literature, which show a higher degree of fatigue for women who have long-Covid.

Further studies will be needed to confirm these preliminary results, but it is likely that this could be the first study to present a valid remedy for the debilitating problem of chronic fatigue, which persists for months after recovering from Sars-Cov-2.

Currently, it appears that targeted nutritional approaches are effective, and the synergies of components of supplements like Apportal® could be incredibly valuable for assisting in recovery of persistent fatigue for post-Covid patients.



Investor Relations Pharmanutra , 050 7846500, investorrelation@pharmanutra.it
Gianluca Gracci, Pharmanutra, +39 345 3646330, g.gracci@pharmanutra.it
Cristina Tronconi, +39 346 0477901, ctronconi@sprianocommunication.com
Matteo Russo, +39 347 9834881, mrusso@sprianocommunication.com

Photo - https://mma.prnewswire.com/media/1485678/ApportAL.jpg
Logo - https://mma.prnewswire.com/media/1391450/PharmaNutra_Logo.jpg

View original content to download multimedia: http://www.prnewswire.com/news-releases/pharmanutra-spa-a-targeted-nutritional-supplement-proves-to-aid-persistent-fatigue-in-post-covid-patients-301266799.html

SOURCE PharmaNutra S.p.A.